Table 5.

Primary colorectal cancer incidence in all GH-treated and non GH-treated patients and in GH-treated patients by gender. SIRs were calculated using SEER data (24) for cases from the USA (n=6, GH-treated and n=5, non GH-treated), and GLOBOCAN data (23) for patients from all other countries (n=5, GH-treated).

Treatment group	Observed cases	Expected cases	SIR (95% CI)
GH-treated (n=6840)	11	18.18	0.60 (0.30–1.08)
Non GH-treated (n=940)	5	3.31	1.51 (0.49–3.52)
GH-treated males (n=3571)	9	12.28	0.73 (0.34–1.39)
GH-treated females (n=3269)	2	5.91	0.34 (0.04–1.22)

CI, confidence interval; SIR, standardized incidence ratio.